Tetsuya Sakai

Tetsuya Sakai

Auto-generated profile, based on publicly available information

Tetsuya Sakai

Department of Thoracic Oncology National Cancer Center Hospital East Kashiwa Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAkira Sugimoto
Akira Sugimoto
SMShingo Matsumoto
Shingo Matsumoto
HUHibiki Udagawa
Hibiki Udagawa
RIRyo Itotani
Ryo Itotani
YUYuko Usui
Yuko Usui
KGKoichi Goto
Koichi Goto
Purpose: We evaluated plasma cell-free DNA (cfDNA) and tissue-based sequencing concordance for comprehensive oncogenic driver detection in non–small cell lung cancer (NSCLC) using a large-scale prospective screening cohort (LC-SCRUM-Liquid). Experimental Design: Blood samples were prospectively collected within 4 weeks of corresponding tumor tissue sampling from patients with advanced NSCLC to investigate plasma cfDNA sequencing concordance for alterations in 8 oncogenes (EGFR, KRAS, BRAF, HER2, MET, ALK, RET, and ROS1) compared with tissue-based next-generation targeted sequencing. Results: Paired blood and tissue samples were obtained in 1,062/1,112 enrolled patients with NSCLC. Oncogenic alteration was detected by plasma cfDNA sequencing and tissue assay in 455 (42.8%) and 537 (50.5%) patients, respectively. The positive percent agreement of plasma cfDNA sequencing compared with tissue DNA and RNA assays were 77% (EGFR, 78%; KRAS, 75%; BRAF, 85%; HER2, 72%) and 47% (ALK, 46%; RET, 57%; ROS1, 18%; MET, 66%), respectively. Oncogenic drivers were positive for plasma cfDNA and negative for tissue due to unsuccessful genomic analysis from poor-quality tissue samples (70%), and were negative for plasma cfDNA and positive for tissue due to low sensitivity of cfDNA analysis (61%). In patients with positive oncogenic drivers by plasma cfDNA sequencing but negative by tissue assay, the response rate of genotype-matched therapy was 85% and median progression-free survival was 12.7 months. Conclusions: Plasma cfDNA sequencing in patients with advanced NSCLC showed relatively high sensitivity for detecting gene mutations but low sensitivity for gene fusions and MET exon 14 skipping. This may be an alternative only when tissue assay is unavailable due to insufficient DNA and RNA. See related commentary by Jacobsen Skanderup et al., p. 1381

1 February 2026 in Journal of Clinical Oncology
Verified
Journal Article
Open access
CRCharles M. Rudin
Charles M. Rudin
MJMelissa L. Johnson
Melissa L. Johnson
LPLuis Paz-Ares
Luis Paz-Ares
MNMakoto Nishio
Makoto Nishio
CHChristine L. Hann
Christine L. Hann
MAMyung-Ju Ahn
Myung-Ju Ahn
PURPOSE: Treatment options for patients with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) are limited. This phase II trial evaluated the efficacy and safety of ifinatamab deruxtecan (I-DXd), a B7 homolog 3–directed antibody-drug conjugate, in patients with previously treated ES-SCLC. METHODS: Patients were randomly assigned to receive I-DXd 8 or 12 mg/kg intravenously once every 3 weeks in part 1 (dose optimization) and received I-DXd 12 mg/kg in part 2 (extension). The primary end point was objective response rate (ORR) by blinded independent central review per RECIST, version 1.1. RESULTS: Overall, 183 patients received I-DXd: 88 in part 1 (8 mg/kg, n = 46; 12 mg/kg, n = 42) and 95 in part 2. The median number of previous lines of treatment was two. In the total 12-mg/kg group from parts 1 and 2 (n = 137), the confirmed ORR was 48.2% (95% CI, 39.6 to 56.9), median duration of response was 5.3 (95% CI, 4.0 to 6.5) months, median time to response was 1.4 (range, 1.0-8.1) months, median progression-free survival was 4.9 (95% CI, 4.2 to 5.5) months, and the 9-month overall survival estimate was 59.1%. Any-grade treatment-related adverse events (TRAEs) occurred in 89.8% of patients (grade ≥3, 36.5%). The most common TRAEs were nausea (43.1%), anemia (34.3%), and neutropenia (34.3%). TRAEs associated with treatment discontinuation and death were reported in 9.5% and 4.4% of patients, respectively. Treatment-related interstitial lung disease (ILD) as determined by the ILD adjudication committee was reported in 12.4% of patients (grade ≥3, 4.4%). CONCLUSION: I-DXd 12 mg/kg once every 3 weeks showed promising efficacy in patients with previously treated ES-SCLC. The observed safety profile was consistent with previous reports, with no new safety signals identified.

3 August 2023 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
TSTetsuya Sakai
Tetsuya Sakai
SMShingo Matsumoto
Shingo Matsumoto
YUYasuto Ueda
Yasuto Ueda
YSYuji Shibata
Yuji Shibata
TITakaya Ikeda
Takaya Ikeda
KGKoichi Goto
Koichi Goto

1 December 2002 in Clinical Nephrology
Verified
Journal Article
Closed access
HSH. Sashiyama
H. Sashiyama
YIY. Irie
Y. Irie
YOY. Ohtake
Y. Ohtake
KNK. Nakajima
K. Nakajima
HYH. Yoshida
H. Yoshida
KOKensuke Okuda
Kensuke Okuda
Acute renal failure with hearing loss due to sodium bromate intoxication is described. A 48-year-old woman who ingested permanent wave neutralizer in a suicide attempt and developed anuria was admitted to our hospital for hemodialysis. Bromate intoxication was suspected and hemodialysis was carried out; she required maintenance dialysis 3 times a week. Irreversible severe sensorineural hearing loss continued and peripheral polyneuropathy developed in the lower limbs. We measured the concentration of bromine in the serum before and after the first hemodialysis and found its removal rate to be 61.3%. This is the first report that proved the utility of hemodialysis for bromate intoxication in a clinical setting.

10 October 2024 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
SUShigeki Umemura
Shigeki Umemura
HUHibiki Udagawa
Hibiki Udagawa
TITakaya Ikeda
Takaya Ikeda
HMHaruyasu Murakami
Haruyasu Murakami
HDHaruko Daga
Haruko Daga
KGKoichi Goto
Koichi Goto

6 October 2026 in Cancer Medicine
Verified
Journal Article
Open access
RYRyo Yoshimaru
Ryo Yoshimaru
HNHirotaka Nakamura
Hirotaka Nakamura
YGYong‐Mei Guo
Yong‐Mei Guo
KMKensuke Matsuda
Kensuke Matsuda
TSTetsuya Sakai
Tetsuya Sakai
JYJunichiro Yuda
Junichiro Yuda
Introduction: Immune‐related adverse events (irAEs) are complications associated with immune checkpoint inhibitors (ICIs). Hematologic irAEs (heme‐irAEs) are rare but potentially serious and may interfere with cancer treatment. However, their clinical characteristics remain insufficiently described. Methods: We conducted a single‐center retrospective study using the National Cancer Center Hospital East medical database from April 1, 2014, to March 31, 2024. Potential heme‐irAE cases were identified using diagnostic name searches, bone marrow examination records, and positive DAT results and were followed by chart review to exclude alternative etiologies, such as chemotherapy‐related myelosuppression, marrow involvement, infection, and hematologic malignancy. Results: Of the 3371 patients treated with ICI‐containing regimens, 40 patients developed heme‐irAEs, indicating an observed incidence of 1.2%. The most common heme‐irAE reported was immune thrombocytopenia, and 85.0% of these events were Grade 3 or higher. The median time from ICI initiation to heme‐irAE onset was 12 weeks. For all affected patients included in the regimen‐specific onset‐time comparison, the median time to heme‐irAE onset appeared shorter with dual ICI therapy without chemotherapy than with ICI monotherapy, although this descriptive comparison was based on a small number of cases. ICI‐containing regimens were interrupted or discontinued in most patients, and systemic corticosteroids were administered to 25 patients, 18 of whom achieved hematologic improvement. Cancer treatment was resumed or continued for 20 patients, with no recurrent heme‐irAEs observed during the follow‐up period. In an exploratory landmark analysis, hematologic response was associated with longer survival after heme‐irAE onset. Conclusion: Heme‐irAEs were rare but frequently severe in this Japanese single‐center cohort. Their occurrence was associated with prolonged interruption of cancer treatment, underscoring the importance of early recognition, careful diagnostic evaluation, and multidisciplinary management of heme‐irAEs. Our findings regarding dual ICI therapy, survival, and subsequent ICI therapy after heme‐irAE onset should be interpreted as exploratory.